Mezagitamab for chronic immune thrombocytopenia
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests a new medicine called mezagitamab for people with chronic ITP (low platelets for over a year). The medicine may help raise your platelet count and reduce bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had ITP for at least 12 months.
- You have had a platelet count below 30,000 at some point.
- You have tried at least one first-line treatment (like steroids) and one second-line treatment (like TPO-RA, rituximab, or fostamatinib), and they did not work well or caused side effects.
- You have not had your spleen removed.
- You have not had a blood clot in the last year.
- You do not have active hepatitis B or C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows up with adults who completed a previous mezagitamab trial for chronic immune thrombocytopenia (ITP). It monitors long-term safety and effectiveness of the treatment.
This trial tests a new drug (belantamab mafodotin) in adults with primary immune thrombocytopenia (ITP) who have already tried at least one other treatment. The goal is to see if the drug can safely raise platelet counts and reduce bleeding risk.
This trial tests combining two antibodies (anti-CD38 and rituximab) for adults with chronic ITP who haven't been helped by steroids or other standard treatments. The goal is to see if this drug pair can raise platelet counts and reduce bleeding risk.
This Phase 3 study tests whether adding an injection called belimumab (or a placebo) to rituximab works better and is safe for adults with long-lasting immune thrombocytopenia (ITP). You may be eligible if your platelet counts stay low despite prior steroid and/or IVIG treatment and if infections, vaccines, and other health conditions meet the study rules.
This study tests whether adding another medicine (telitacicept) to a standard platelet-boosting drug (eltrombopag) works better than eltrombopag alone for adults with ITP that hasn't improved with steroids. The goal is to help raise your platelet counts and reduce bleeding risk.
This trial tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with long-term immune thrombocytopenia (ITP) who have already tried steroids without lasting success.
Hear when a new Immune Thrombocytopenic Purpura (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.